Plasma Protein Therapeutic Market
Report ID: SQMIG35I2715
Report ID: SQMIG35I2715
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35I2715 |
Region:
Global |
Published Date: May, 2026
Pages:
157
|Tables:
150
|Figures:
78
Global Plasma Protein Therapeutic Market size was valued at USD 29.5 Billion in 2024 and is poised to grow from USD 31.42 Billion in 2025 to USD 52.0 Billion by 2033, growing at a CAGR of 6.5% during the forecast period (2026-2033).
Plasma protein therapeutics are biologics produced from donated human plasma. The major driver for the market is rising clinical need for replacement and immunomodulatory therapies. This sector is important because these products are essential treatments for conditions such as primary immunodeficiency, bleeding disorders and acute critical care situations, and they create dependency within healthcare systems. The field has matured over the past decades with the improvement of the technology of fractionation and the expansion of dedicated infrastructure for plasma collection allowing higher yields and wider geographic reach. Clinical adoption altered commercial priorities, for example intravenous immunoglobulin became a staple in neurology and autoimmune care from a niche therapy.
Building on the clinical momentum established earlier, the main driver of growth is the resilience of plasma supply, as the availability of plasma influences production volumes, pricing and market reach. As donor recruitment and fractionation capacity increase, manufacturers expand immunoglobulin and factor production, reducing unit costs and increasing access in middle‑income settings where needs were previously unmet. Supply shocks, in contrast, lead to rationing and investment in collection centres and alternative platforms as seen when pandemic shocks boosted capital flows into plasma networks. Wider use of IVIG for autoimmune neuropathies has been made possible by expanded supply in real use and has spurred the development of hyperimmune preparations to counter emerging infectious threats globally.
How is AI improving patient outcomes in the plasma protein therapeutics market?
AI is helping patients in the plasma protein therapeutics market by enhancing donor screening, accelerating protein design and boosting manufacturing quality. Machine learning picks the best donors, computer vision speeds up lab testing, and generative models help design therapeutic proteins. The clinical setting continues to be a complex challenge in terms of supply and need, and the market is embracing these tools and donation centers and R&D teams are starting to incorporate AI into their day-to-day.” For example, CSL will launch AI tools in May 2025 to improve donor suitability. At Takeda, AI microscopy automates plasma testing, freeing scientists for higher-value work
CSL launched the Plasma Medical Quick Search to US donation centers in May 2025. This AI implementation helped improve donor matching and collection efficiency, facilitating a steadier supply and faster access to therapies for patients, while cutting down on wasted resources and helping manufacturers forecast demand more reliably.
Market snapshot - (2026-2033)
Global Market Size
USD 29.5 Billion
Largest Segment
Immunoglobulins
Fastest Growth
Immunoglobulins
Growth Rate
6.5% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global plasma protein therapeutic market is segmented by product type, application, route of administration, distribution channel, end user and region. Based on product type, the market is segmented into Immunoglobulins, Coagulation Factors, Albumin, Alpha-1 Proteinase Inhibitors and Others. Based on application, the market is segmented into Immunodeficiency Diseases, Hemophilia, Neurological Disorders, Liver Diseases, Pulmonary Disorders and Others. Based on route of administration, the market is segmented into Intravenous and Subcutaneous. Based on distribution channel, the market is segmented into Hospitals, Specialty Clinics, Retail Pharmacies and Online Pharmacies. Based on end user, the market is segmented into Hospitals, Ambulatory Surgical Centers, Specialty Care Centers and Homecare Settings. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
The immunoglobulins segment holds the largest share owing to its ability to treat a wide range of immune deficiencies and inflammatory conditions, which results in steady demand in clinical settings and physician preference. Routine prescribing is enabled by established treatment guidelines, clinician familiarity and payer coverage, and reliable availability is ensured by mature manufacturing and supply chain infrastructure. The steady investment and market preference for immunoglobulin therapies in the plasma protein therapeutic market are attributed to broad indications, clinical acceptance and scale of production.
But the fastest growing area is coagulation factors. Recombinant and extended half-life formulations have led to wider prophylactic use and improved patient convenience. Increased regulatory momentum for new products, expanded diagnostic reach and targeted investment are driving the uptake of therapies and new market opportunities across treatment settings.
The intravenous segment dominates because this route provides rapid systemic delivery and is the preferred route for high dose plasma protein therapies that require controlled infusion and clinical monitoring. History of hospital and clinic infusion practices, established safety protocols and clinician experience support the use in complex indications. Existing payer infrastructures and infusion frameworks are conducive to routine intravenous administration, supporting its central role in the treatment pathways of various plasma-derived products.
But the fastest growth is in subcutaneous administration, driven by patient desire for convenient home dosing and advances in formulations and delivery devices that support stable low-volume injections. Adoption is being driven by increased support for outpatient care and a developer focus on intuitive presentations, as well as expanding access and creating new commercial opportunities.
To get detailed segments analysis, Request a Free Sample Report
North America is the biggest global market for plasma protein therapeutics with strong research infrastructure, a wealth of industry expertise and an end-to-end supply chain of plasmapheresis, fractionation and biologics manufacturing. The close interaction between academic centers, specialized plasma collection networks and established biotechnology and pharmaceutical companies allows rapid translation of novel therapies into clinical practice. Regulatory frameworks enabling the approval and reimbursement of advanced therapies provide incentives for investment and commercialisation. Mature clinical trial ecosystems and powerful patient advocacy groups also assist plasma derived and recombinant protein therapeutics. Production can be scaled to address different therapeutic needs with manufacturing capacity and strategic partnerships across the value chain providing resilience.
The United States plasma protein therapeutic market is characterized by large collection networks and advanced fractionation and specialty manufacturing assets. Close collaboration between industry, academic research centers and clinical networks is supporting therapeutic development and adoption. Strong regulator engagement and alignment with payers enable commercialization of complex plasma derived and recombinant products Resilient supply chains are delivered through strategic partnerships and targeted expertise. Focus on quality systems results in responsiveness to therapeutic demand in several indication areas.
The Canada Plasma Protein Therapeutic Market is driven by the robust plasma collection infrastructure and regional fractionation and specialty biologics manufacturing. Collaborative research between universities, hospitals and industry to speed clinical development and a focus on regulatory compliance to build provider and payor confidence Strategic cross-border partnerships and manufacturing capabilities investments strengthen supply resilience and therapeutic availability across immune and genetic indications. Quality systems and clinical collaboration allow uptake and access to therapy.
A combination of strong clinical research networks, progressive regulatory harmonization and growing adoption of specialized plasma derived and recombinant therapies within healthcare systems is causing Europe to expand rapidly. Investment in advanced manufacturing capacity and regional fractionation facilities has enhanced supply continuity while enabling localization of complex biologics production. Partnerships between industry, academia and patient groups speed up the development of therapies and the generation of real-world evidence. Market maturation in key countries underpins diversified product portfolios and adaptable distribution channels while policy frameworks increasingly recognize the value of plasma protein therapeutics, enabling wider access and integration into standard care across multiple therapeutic areas. Public-private partnerships and targeted funding mechanisms drive translational research, and increasing clinical expertise and specialist centres promote adoption in rare disease and immunology indications.
Plasma Protein Therapeutics Industry Germany benefits from a strong domestic manufacturing base, wide ranging plasma collection networks and a concentrated community of specialist clinical centres. The development and clinical testing of advanced therapeutics requires close collaboration between industry and academic research. Commercialization of plasma derived and recombinant products are enabled by proactive regulatory engagement and established reimbursement frameworks. The investment in fractionation technology and quality systems ensures the reliability of national supply and specialization in immunology and hematology treatments.
Plasma Protein Therapeutic Market| IndustryARC United Kingdom represents a vibrant setting for uptake of new plasma protein therapies, with a strong clinical and research infrastructure. Investment in specialized centers and translational partnerships improves capacity for clinical evaluation and early access. Value in niche and rare disease indications is increasingly recognized in regulatory dialogue and payer engagement. Trial and implementation in specialized treatment areas is facilitated by collaborative networks linking industry, academia and patient groups.
Global Plasma Protein Therapeutics Market France is characterized by growing research collaboration and targeted investment in biologics manufacturing to speed up the development of therapeutics. Integrated networks between hospitals, research institutes and biotech companies support clinical evaluation and early adoption. Ongoing discussions on progressive reimbursement and increasing specialist capacity allow for wider access to plasma derived and recombinant therapies. Quality systems and partnerships are based on supply resilience and expanding treatment options in many clinical areas.
“Asia Pacific is solidifying its position in the plasma protein therapeutics market through strategic capacity expansion in plasma collection and processing, increasing investment in biologics manufacturing and increased participation in global research collaborations. Modernizing regional regulations and aligning pathways promotes clinical development and cross-border access to innovative therapies. Adoption in the different healthcare systems is driven by the increase in clinical expertise and availability of specialized treatment centers. Public private partnerships are being promoted for capacity building and technology transfer. Strategic localisation of manufacturing and active engagement in global supply networks creates resilience and provides a platform to scale up production and introduce new plasma derived and recombinant treatments to meet regional clinical needs. The region’s competitiveness and ability to produce complex protein therapeutics is being enhanced by national biomanufacturing policies, workforce development programs, and the use of international quality standards.
Plasma Protein Therapeutics Market in Japan has a strong biopharmaceutical infrastructure, a well-established clinical research network and deep manufacturing expertise. Universities, hospitals and industry collaborate to support the clinical evaluation and improvement of plasma derived and recombinant therapies. Active regulatory engagement and high quality standards provide routes to approval and provider confidence. Targeted efforts to build manufacturing capacity and workforce skills build supply resilience and adoption They’re also expanding access to a range of specialty treatments.
Market for Plasma Protein Therapeutics South Korea is forging ahead on the basis of increased plasma collection and fractionation capacity, biotech know-how and international cooperation. Government policies encouraging biopharmaceutical innovation and technology transfer fast-track the development of plasma derived and recombinant therapeutics. Increased clinical expertise and specialist centres resulting in improved trial capacity and uptake of therapies • Enhance quality systems and strategic alliances to boost supply resilience and access. These advances pave the way for more therapeutic options across disease areas.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Rising Demand For Immunotherapies
Advances In Fractionation Technology
Limited Plasma Supply Availability
High Regulatory And Compliance Burden
Request Free Customization of this report to help us to meet your business objectives.
Competitive dynamics in the global plasma protein therapeutics market revolve around securing plasma supply, scaling fractionation and developing recombinant or engineered alternatives, prompting targeted M&A, capacity buys, and platform partnerships. Recent strategic moves include Grifols acquiring GigaGen and additional US plasma collection centers to bolster immunoglobulin and recombinant capabilities, and Amgen partnering with a generative biology company to access AI driven protein design.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global plasma protein therapeutic market is positioned for sustained expansion as aging populations and broader clinical adoption increase need for replacement and immunomodulatory biologics. One key driver is rising clinical demand for immunotherapies and replacement therapies. A second driver is advances in fractionation technology that improve yield, safety and scalability. One restraint is limited plasma supply availability, which constrains production volumes and access. North America dominates the market thanks to extensive plasma collection networks, manufacturing capacity and supportive regulatory frameworks, while immunoglobulins remain the dominating segment due to broad indications, clinician familiarity and established supply chains.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 29.5 Billion |
| Market size value in 2033 | USD 52.0 Billion |
| Growth Rate | 6.5% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Plasma Protein Therapeutic Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Plasma Protein Therapeutic Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Plasma Protein Therapeutic Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Plasma Protein Therapeutic Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Plasma Protein Therapeutic Market size was valued at USD 29.5 Billion in 2024 and is poised to grow from USD 31.42 Billion in 2025 to USD 52.0 Billion by 2033, growing at a CAGR of 6.5% during the forecast period (2026-2033).
Competitive dynamics in the global plasma protein therapeutics market revolve around securing plasma supply, scaling fractionation and developing recombinant or engineered alternatives, prompting targeted M&A, capacity buys, and platform partnerships. Recent strategic moves include Grifols acquiring GigaGen and additional US plasma collection centers to bolster immunoglobulin and recombinant capabilities, and Amgen partnering with a generative biology company to access AI driven protein design. 'CSL Behring', 'Takeda Pharmaceutical Company', 'Grifols', 'Kedrion Biopharma', 'Octapharma', 'ADMA Biologics', 'China Biologic Products Holdings', 'GC Biopharma', 'Biotest', 'LFB Group', 'Emergent BioSolutions', 'Bharat Serums and Vaccines', 'Intas Pharmaceuticals', 'Shire Human Genetic Therapies', 'Kamada', 'PlasmaGen BioSciences', 'Hualan Biological Engineering', 'Sanquin Plasma Products', 'Shanghai RAAS Blood Products', 'Bio Products Laboratory'
Greater clinical adoption of immunotherapies and replacement therapies has elevated demand for plasma derived proteins, prompting manufacturers to expand production capacity and prioritize research into improved formulations and distribution channels. Clinicians increasingly rely on these biologics for chronic and acute indications, which reinforces investment in supply chains and incentivizes innovation in stabilization and administration. Payers and healthcare systems respond by integrating plasma protein therapies into treatment protocols, creating predictable procurement patterns and encouraging long term strategic partnerships between producers and healthcare providers, thereby sustaining market expansion.
Expansion Of Therapeutic Indications: Plasma protein therapeutics are being applied to a wider array of clinical areas as deeper biological insights reveal novel targets and patient segments. Manufacturers and clinicians are collaborating to pursue label expansions, combination regimens, and personalized dosing approaches that address autoimmune, neurological, and rare conditions. This trend supports differentiated product strategies, greater specialist engagement, and tailored market access planning, encouraging investment in clinical evidence generation and disease-specific value propositions to broaden treatment options and improve patient outcomes.
Why does North America Dominate the Global Plasma Protein Therapeutic Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
